References
- Heits F, Katschinshki D M, Wilmsen U, Wiedemann G J, Jelkmann W. Serum thrombopoietin and interleukin 6 concentrations in tumor patients and response to chemotherapy-induced thrombocytopenia. Eur J Haematol 1997; 59: 53–58
- Tafuri A, Lemoli R M, Petrucci M T, Ricciardi M R, Fogli M, Bonsi L, Ariola C, Strippoli P, Gregorj C, Petti M C, Tura S, Mandelli F, Bagnara G P. Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells. Exp Hematol 1999; 27: 1255–1263
- Wendling F. Thrombopoientin: its role from early heatopoiesis to platelet production. Haematologica 1999; 84: 158–166
- Koller C, Nebiyou Bekele B, Zhou X, Park C, Estror Z, O'Brien S, et al. Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukaemia. Blood 2006; 108: 1001–1006
- Cheson B D, Bennett J M, Grever M, Kay N, Keating M J, O'Brien S, Rai K R. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guideline for diagnosis and treatment. Blood 1996; 87: 4990–4997
- Rozman C, Montserrat E, Rodríguez-Fernández J M, Ayats R, Vallespí T, Parody R, Ríos A, Prados D, Morey M, Gomis F, et al. Bone marrow histologic pattern – the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64: 642–653
- Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62: 567–575
- Messmer B T, Messmer D, Allen S L, Kolitz J E, Kudalkar P, Cesar D, Murphy E J, Koduru P, Ferrarini M, Zupo S, Cutrona G, Damle R N, Wasil T, Rai K R, Hellerstein M K, Chiorazzi N. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755–764
- Cutrona G, Colombo M, Matis S, Reverberi D, Dono M, Tarantino V, Chiorazzi N, Ferrarini M B. Lymphocytes in humans express ZAP-70 when activated in vivo. Eur J Immunol 2006; 36: 558–569
- Agnelli L, Bicciato S, Mattioli M, Fabris S, Intini D, Verdelli D, Baldini L, Morabito F, Callea V, Lombardi L, Neri A. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 2005; 23: 7296–7306
- Molica S. Progression and survival studies in early chronic lymphocytic leukemia. Blood 1991; 78: 895–899
- Cerutti A, Custodi P, Duranti M, Cazzola M, Balduini C L. Circulating thrombopoietin in reactive conditions behaves like an acute phase reactant. Clin and Lab Haematol 1999; 21: 271–275
- Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman S M, Schulman P, Vinciguerra V P, Rai K R, Ferrarini M, Chiorazzi N. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847
- Hamblin T J, Davis Z, Gardiner A, Oscier D G, Stevenson F K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854
- Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé S, López-Guillermo A, Campo E, Montserrat E. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775
- Rassenti L Z, Huynh L, Toy T L, Chen L, Keating M J, Gribben J G, Neuberg D S, Flinn I W, Rai K R, Byrd J C, Kay N E, Greaves A, Weiss A, Kipps T J. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893–901